The aim of this protocol is to study the deleterious impact of adjuvant chemotherapy or neoadjuvant chemotherapy on ovarian reserve in young women suffering from breast cancer. A new relevant ovarian reserve marker, serum Anti-Mullerian Hormone, will be used in order to evaluate precisely the impact of chemotherapy on ovaries during chemotherapy administrations and after during follow-up (24 months). This strategy offers 2 main advantages : no modification of the traditional care of patients (treatment, organisation, follow up …) and use of a non invasive marker (serum). The final objective is to give precise information to patients on their future fertility after remission.
Study Type
OBSERVATIONAL
Enrollment
250
Institut Bergonié
Bordeaux, France
Centre François BACLESSE
Caen, France
Centre Jean Perrin
Clermont-Ferrand, France
CRLC de Bourgogne Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre de Lutte Contre le Cancer Léon Bérard
Lyon, France
Centre Val d'Aurelle - Paul Lamarque
Montpellier, France
Institut Curie
Paris, France
Institut Jean Godinot
Reims, France
Centre Eugène Marquis
Rennes, France
...and 1 more locations
To evaluate the effects of adjuvant or neoadjuvant chemotherapy treatment on ovarian reserve for in situ breast cancer patients
Serum anti-Müllerian hormone concentration will be measured at each chemotherapy administration and 24 months follow-up after chemotherapy completion
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.